BR112014018247A8 - Pré-mistura de potássio de raltegravir amorfa e estável; processo; formulação farmacêutica; e método - Google Patents

Pré-mistura de potássio de raltegravir amorfa e estável; processo; formulação farmacêutica; e método

Info

Publication number
BR112014018247A8
BR112014018247A8 BR112014018247A BR112014018247A BR112014018247A8 BR 112014018247 A8 BR112014018247 A8 BR 112014018247A8 BR 112014018247 A BR112014018247 A BR 112014018247A BR 112014018247 A BR112014018247 A BR 112014018247A BR 112014018247 A8 BR112014018247 A8 BR 112014018247A8
Authority
BR
Brazil
Prior art keywords
amorphous
stable
pharmaceutical formulation
raltegravir potassium
potassium premix
Prior art date
Application number
BR112014018247A
Other languages
English (en)
Other versions
BR112014018247A2 (pt
Inventor
Kumar Arora Surinder
Tukaram Singare Dnyaneshwar
Dattatreya Galande Amol
Chandra Ray Purna
Gopalkrishna Saoji Dilip
Avachat Makrand
Pal Singh Girij
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR112014018247A2 publication Critical patent/BR112014018247A2/pt
Publication of BR112014018247A8 publication Critical patent/BR112014018247A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PRÉ-MISTURA DE POTÁSSIO DE RALTEGRAVIR AMORFA E ESTÁVEL; PROCESSO; FORMULAÇÃO FARMACÊUTICA; E MÉTODO. Trata-se de uma pré-mistura de potássio de Raltegravir amorfa e estável, método de produção e composição farmacêutica da mesma.
BR112014018247A 2012-01-25 2013-01-25 Pré-mistura de potássio de raltegravir amorfa e estável; processo; formulação farmacêutica; e método BR112014018247A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN72KO2012 2012-01-25
PCT/IB2013/050643 WO2013111100A1 (en) 2012-01-25 2013-01-25 Stable amorphous raltegravir potassium premix and process for the preparation thereof

Publications (2)

Publication Number Publication Date
BR112014018247A2 BR112014018247A2 (pt) 2017-06-20
BR112014018247A8 true BR112014018247A8 (pt) 2017-07-11

Family

ID=47754907

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018247A BR112014018247A8 (pt) 2012-01-25 2013-01-25 Pré-mistura de potássio de raltegravir amorfa e estável; processo; formulação farmacêutica; e método

Country Status (12)

Country Link
US (1) US20150328215A1 (pt)
EP (1) EP2806857A1 (pt)
JP (1) JP2015504913A (pt)
KR (1) KR20140114406A (pt)
CN (1) CN104093400A (pt)
AU (1) AU2013213255A1 (pt)
BR (1) BR112014018247A8 (pt)
CA (1) CA2863575A1 (pt)
MX (1) MX2014009015A (pt)
RU (1) RU2014134257A (pt)
WO (1) WO2013111100A1 (pt)
ZA (1) ZA201405247B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2942239C (en) * 2014-03-21 2020-09-22 Mylan Laboratories Ltd. A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
CN104146949A (zh) * 2014-08-29 2014-11-19 宁夏泰瑞制药股份有限公司 一种延胡索酸泰妙菌素预混剂及其制备方法
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0213522C1 (pt) 2001-10-26 2021-05-25 St Di Ricerche Di Biologia Molecolare P Angeletti S P A compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CN101161244A (zh) * 2006-10-13 2008-04-16 上海世康特制药有限公司 尼莫地平片剂及其制备方法
US8742105B2 (en) 2009-06-02 2014-06-03 Hetero Research Foundation Polymorphs of raltegravir potassium
US20120093738A1 (en) * 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
WO2011024192A2 (en) * 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
SI2545048T1 (sl) * 2010-04-01 2014-12-31 Teva Pharmaceutical Industries Ltd. Soli Raltegravirja in njegove kristalinične oblike
EP2575465A4 (en) * 2010-05-25 2013-11-20 Hetero Research Foundation Raltegravir SALTS

Also Published As

Publication number Publication date
US20150328215A1 (en) 2015-11-19
CN104093400A (zh) 2014-10-08
WO2013111100A9 (en) 2014-08-14
AU2013213255A9 (en) 2016-06-16
JP2015504913A (ja) 2015-02-16
KR20140114406A (ko) 2014-09-26
BR112014018247A2 (pt) 2017-06-20
MX2014009015A (es) 2014-12-08
AU2013213255A1 (en) 2014-08-07
ZA201405247B (en) 2015-12-23
EP2806857A1 (en) 2014-12-03
WO2013111100A1 (en) 2013-08-01
CA2863575A1 (en) 2013-08-01
RU2014134257A (ru) 2016-03-20

Similar Documents

Publication Publication Date Title
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
CL2017003067A1 (es) Piridinas sustituidas y método de uso
BR112013030472A2 (pt) formulação farmacêutica, artigo de fabricação e método
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
ECSP13012877A (es) FORMAS SÓLIDAS SDE 3- (5-AMINO-2-metil -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, Y SUS COMPOSICIONES FARMACÉUTICAS Y USOS
BR112014010391A2 (pt) composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
CR20150250A (es) Nuevos derivados de piridina
UY34772A (es) ?una formulación de fármaco de liberación retardada?.
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
ECSP13013008A (es) Imidazopiridazinas como inhibidores de quinasa akt
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
BR112014011314A2 (pt) espessante, processo apara preparar um espessante, formulação ácida, usos de uma formulação ácida, de uma formulação alcalina, e de um espessante, e, formulação alcalina
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
BR112017005109A2 (pt) produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário
BR112015013738A2 (pt) composição de fibras de tomate, método de fabricação de um produto selecionado de um alimento, uma bebida e uma formulação nutricional, produto e processo de fabricação de uma composição de fibras de tomate
BR112015011838A2 (pt) composição, método de formação de um revestimento hidrofóbico sobre uma superfície, revestimento hidrofóbico e processo de preparação de composição
BR112013022930A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, processo para produzir uma composição farmacêutica
BR112014018247A8 (pt) Pré-mistura de potássio de raltegravir amorfa e estável; processo; formulação farmacêutica; e método

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]